我们如何改进将新证据转化为造血细胞移植和细胞治疗的实践?

IF 6.9 2区 医学 Q1 HEMATOLOGY
Mark Juckett , Christopher Dandoy , Zachariah DeFilipp , Tamila L. Kindwall-Keller , Stephen R. Spellman , Celalettin Ustun , Bryce M. Waldman , Daniel J. Weisdorf , William A. Wood , Mary M. Horowitz , Linda J. Burns , Nandita Khera
{"title":"我们如何改进将新证据转化为造血细胞移植和细胞治疗的实践?","authors":"Mark Juckett ,&nbsp;Christopher Dandoy ,&nbsp;Zachariah DeFilipp ,&nbsp;Tamila L. Kindwall-Keller ,&nbsp;Stephen R. Spellman ,&nbsp;Celalettin Ustun ,&nbsp;Bryce M. Waldman ,&nbsp;Daniel J. Weisdorf ,&nbsp;William A. Wood ,&nbsp;Mary M. Horowitz ,&nbsp;Linda J. Burns ,&nbsp;Nandita Khera","doi":"10.1016/j.blre.2023.101079","DOIUrl":null,"url":null,"abstract":"<div><p>The field of hematopoietic cell transplantation<span><span><span> and cell therapy (HCT/CT) is advancing rapidly to bring an ever-expanding collection of potentially curative therapies to patients with malignant and non-malignant </span>diseases<span>. The impact of these therapies depends on our ability to implement them as new evidence becomes available to advance the quality of care. There is often a long delay between evidence development and adoption of therapies based on that evidence into clinical practice. In this review, we describe the potential factors based on an implementation framework that could act as facilitators or barriers to adoption of therapies in the context of HCT/CT. We highlight two examples, the first to showcase the efforts to improve the efficiency of adoption of new findings and accelerate improvement in care of HCT/CT patients and the second to discuss the challenges in real world implementation of chimeric antigen receptor </span></span>T cell therapy. We conclude by reviewing strategies to improve translation of evidence and ways to measure their success.</span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330269/pdf/","citationCount":"0","resultStr":"{\"title\":\"How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?\",\"authors\":\"Mark Juckett ,&nbsp;Christopher Dandoy ,&nbsp;Zachariah DeFilipp ,&nbsp;Tamila L. Kindwall-Keller ,&nbsp;Stephen R. Spellman ,&nbsp;Celalettin Ustun ,&nbsp;Bryce M. Waldman ,&nbsp;Daniel J. Weisdorf ,&nbsp;William A. Wood ,&nbsp;Mary M. Horowitz ,&nbsp;Linda J. Burns ,&nbsp;Nandita Khera\",\"doi\":\"10.1016/j.blre.2023.101079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The field of hematopoietic cell transplantation<span><span><span> and cell therapy (HCT/CT) is advancing rapidly to bring an ever-expanding collection of potentially curative therapies to patients with malignant and non-malignant </span>diseases<span>. The impact of these therapies depends on our ability to implement them as new evidence becomes available to advance the quality of care. There is often a long delay between evidence development and adoption of therapies based on that evidence into clinical practice. In this review, we describe the potential factors based on an implementation framework that could act as facilitators or barriers to adoption of therapies in the context of HCT/CT. We highlight two examples, the first to showcase the efforts to improve the efficiency of adoption of new findings and accelerate improvement in care of HCT/CT patients and the second to discuss the challenges in real world implementation of chimeric antigen receptor </span></span>T cell therapy. We conclude by reviewing strategies to improve translation of evidence and ways to measure their success.</span></p></div>\",\"PeriodicalId\":56139,\"journal\":{\"name\":\"Blood Reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330269/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0268960X23000401\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000401","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

造血细胞移植和细胞治疗(HCT/CT)领域正在迅速发展,为恶性和非恶性疾病患者带来了越来越多的潜在治疗方法。这些疗法的影响取决于我们实施它们的能力,因为有了新的证据来提高护理质量。在证据的开发和基于该证据的治疗方法进入临床实践之间通常会有很长的延迟。在这篇综述中,我们描述了基于实施框架的潜在因素,这些因素可能会成为HCT/CT背景下采用疗法的促进者或障碍。我们重点介绍了两个例子,第一个例子展示了提高采用新发现的效率和加快改善HCT/CT患者护理的努力,第二个例子讨论了嵌合抗原受体T细胞治疗在现实世界中实施的挑战。最后,我们回顾了改进证据翻译的策略以及衡量其成功与否的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?

The field of hematopoietic cell transplantation and cell therapy (HCT/CT) is advancing rapidly to bring an ever-expanding collection of potentially curative therapies to patients with malignant and non-malignant diseases. The impact of these therapies depends on our ability to implement them as new evidence becomes available to advance the quality of care. There is often a long delay between evidence development and adoption of therapies based on that evidence into clinical practice. In this review, we describe the potential factors based on an implementation framework that could act as facilitators or barriers to adoption of therapies in the context of HCT/CT. We highlight two examples, the first to showcase the efforts to improve the efficiency of adoption of new findings and accelerate improvement in care of HCT/CT patients and the second to discuss the challenges in real world implementation of chimeric antigen receptor T cell therapy. We conclude by reviewing strategies to improve translation of evidence and ways to measure their success.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信